Court Dismisses Privacy Claims Against IQVIA in Rose v. IQVIA Holdings Inc.
A federal court dismissed privacy-related claims against IQVIA regarding its operation of Drugs.com, citing the plaintiffs' failure to specify their search history.
Stocks · News reference
Stifel analyst Shlomo Rosenbaum maintains IQVIA Holdings (NYSE:IQV) with a Buy and raises the price target from $276 to $303.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
A federal court dismissed privacy-related claims against IQVIA regarding its operation of Drugs.com, citing the plaintiffs' failure to specify their search history.
IQVIA projected that U.S. peak annual sales for products utilizing GENFIT's technology could exceed $1.5 billion by 2033.
Rothschild & Co Redburn has increased its price target for IQVIA Holdings Inc. from $287 to $299.
Truist has increased its price target for IQVIA Holdings Inc. while maintaining a Buy rating on the stock.
IQVIA Holdings Inc. announced its third-quarter 2026 financial results, reporting revenue of $4.43 billion and adjusted earnings per share of $3.34.